Palatin Technologies (NYSEAMERICAN:PTN) Trading 27.8% Higher – What’s Next?

Palatin Technologies (NYSEAMERICAN:PTN) was up 27.8% during trading on Wednesday . The company traded as high as $9.58 and last traded at $9.47. 180,166 shares traded hands during mid-day trading, an increase of 769% from the average session volume of 20,741 shares. The stock had previously closed at $7.41.

Palatin Technologies Trading Down 6.4%

The firm’s 50 day moving average price is $10.11 and its two-hundred day moving average price is $15.73.

Palatin Technologies (NYSEAMERICAN:PTN) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.87. The company had revenue of $3.92 million for the quarter, compared to analysts’ expectations of $1.28 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Bleichroeder LP acquired a new position in shares of Palatin Technologies in the fourth quarter valued at approximately $120,000. Jane Street Group LLC purchased a new stake in shares of Palatin Technologies during the fourth quarter worth approximately $166,000. Millennium Management LLC acquired a new stake in shares of Palatin Technologies during the fourth quarter worth $206,000. Geode Capital Management LLC acquired a new stake in shares of Palatin Technologies during the fourth quarter worth $272,000. Finally, Superstring Capital Management LP purchased a new position in Palatin Technologies in the 4th quarter valued at $522,000. 11.50% of the stock is currently owned by hedge funds and other institutional investors.

About Palatin Technologies

Palatin Technologies, Inc (NYSE American: PTN) is a clinical-stage biopharmaceutical company focused on the development of receptor-targeted peptide therapeutics. The company concentrates on designing and advancing peptide- and small-molecule programs that selectively target specific receptor systems with the goal of treating endocrine, inflammatory and cardiovascular-related disorders. Palatin’s approach emphasizes receptor specificity to improve therapeutic profiles and reduce off-target effects commonly seen with less selective agents.

Palatin’s activities center on preclinical and clinical development, regulatory interaction and the pursuit of strategic partnerships or licensing arrangements to support late-stage development and commercialization.